Looking for 1254053-84-3 / Gilteritinib Fumarate API manufacturers, exporters & distributors?
Gilteritinib Fumarate manufacturers, exporters & distributors
1
45
PharmaCompass offers a list of Gilteritinib Fumarate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Gilteritinib Fumarate manufacturer or Gilteritinib Fumarate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Gilteritinib Fumarate manufacturer or Gilteritinib Fumarate supplier.
API | Excipient name
Gilteritinib Fumarate
Synonyms
Gilteritinib hemifumarate, Asp-2215 hemifumarate, 1254053-84-3, Gilteritinib fumarate [usan], Asp2215 hemifumarate, 5rzz0z1gjt
Unique Ingredient Identifier (UNII)
5RZZ0Z1GJT
About Gilteritinib Fumarate
Gilteritinib Fumarate is the fumarate salt form of gilteritinib, an orally bioavailable inhibitor of the receptor tyrosine kinases (RTKs) FMS-like tyrosine kinase 3 (FLT3; STK1; FLK2), AXL (UFO; JTK11), anaplastic lymphoma kinase (ALK; CD246), and leukocyte receptor tyrosine kinase (LTK), with potential antineoplastic activity. Upon administration, gilteritinib binds to and inhibits both the wild-type and mutated forms of FLT3, AXL, ALK and LTK. This may result in an inhibition of FLT3-, AXL-, ALK-, and LTK-mediated signal transduction pathways and reduced proliferation in cancer cells that overexpress these RTKs. FLT3, AXL, ALK, and LTK, which are overexpressed or mutated in a variety of cancer cell types, play key roles in tumor cell growth and survival.